Results 51 to 60 of about 2,387 (195)

Cross‐Neutralizing and Broadly Neutralizing Human Antibodies Against Nonenveloped Viruses

European Journal of Immunology, Volume 56, Issue 10, October 2026.
In this review article, Marchand et al. compare cross ‐ and broadly ‐neutralizing human antibodies against non ‐ enveloped viruses from several major families, discussing their structural characteristics, neutralization mechanisms and relevance for the development of antiviral vaccines and therapeutics.
Sarah Marchand, Samy Taouli, Dorian McIlroy   +2 more
wiley   +1 more source

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Human Vaccines & Immunotherapeutics
The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal ...
Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten   +10 more
doaj   +1 more source

Vaccination in pediatric transplantation—General recommendations. A position paper by the European Reference Network TransplantChild

Journal of Pediatric Gastroenterology and Nutrition, Volume 83, Issue 4, Page 624-636, October 2026.
Abstract Infectious diseases remain a leading cause of morbidity and mortality among pediatric transplant recipients, despite significant advances in transplantation management. Vaccination is the most effective strategy to prevent infections; however, its efficacy is hindered in solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT)
Valeria Casotti, Francesco Saglio, Adriana Balduzzi, Peter Barany, Vibeke Brix Christensen, Simona Buelli, Daniele Donà, Maja Klaudel‐Dreszler, Sara Mosca, Andrea Pietrobattista, Michele Pinon, Giusy Ranucci, Lars Wennberg, Lorenzo D'Antiga, ERN TransplantChild Working Group, Claudia Vittori, Manuela Tumino, B. Ruben Brandsema, Lisa Swartling, Silvia Garazzino, Carlo Pace Napoleone, Kai Lehmberg, Isabella Guzzo, Charlotte Roy, Nicola Pradegan, Silvia Simo Nebot, Maria Herthelius, Angelo Mazza, Enrico Aidala, Oleg Godik, Victoria Bordon Cueto De Braem, Marco Busutti, Emily Claire Argento, Marc Garcia Lorenzo, Timo Jahnukainen, Zoryana Ivanyuk   +35 more
wiley   +1 more source

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

, 2023
International audienceAbstract In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in ...
Amanda Leach, Wählby Hamrén, Ulrika, Mankad, Vaishali, Cabañas, Fernando, Fernando Cabañas, Domachowske, Joseph, Nguyen, Kim A, Kubiak, Robert J, Atanasova, Victoria, Victoria Atanasova, Furuno, Kenji, Robert J Kubiak, Ulrika Wählby Hamrén, Kubiak, Robert, Therese Takas, Leach, Amanda, Banu, Irfana, Nguyen, Kim An, Manish Shroff, Chang, Yue, Kenji Furuno, Kim A Nguyen, Shroff, Manish, Takas, Therese, Joseph B Domachowske, Vaishali S Mankad, Irfana Banu, Tonya Villafana, Yue Chang, Domachowske, Joseph B, Mankad, Vaishali S, Villafana, Tonya   +31 more
core   +1 more source

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

New England Journal of Medicine, 2020
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.In this trial ...
Pamela Griffin M., Yuan Y., Takas T., Domachowske J. B., Madhi S. A., Manzoni P., Simoes E. A. F., Esser M. T., Khan A. A., Dubovsky F., Villafana T., DeVincenzo J. P.   +11 more
openaire   +5 more sources

Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation.
Susanna Esposito, Matteo Puntoni, Giuseppe Maglietta, Alessandro De Fanti, Chiara Ghizzi, Giacomo Biasucci, Federico Marchetti, Melodie Olivia Aricò, Gianluca Vergine, Marcello Stella, Battista Guidi, Agnese Suppiej, Francesca Alberghi, Emanuele Filice, Maria Elena Capra, Enrico Valletta, Andrea Miceli, Cristina Malaventura, Beatrice Rita Campana, Valentina Fainardi, Caterina Caminiti   +20 more
doaj   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, Robert Musci, Jeroen Geurtsen, Leonard R. Krilov   +10 more
doaj   +1 more source

RSV‐Pre‐F Vaccination During Pregnancy and Neonatal Outcomes—A Systematic Review and Meta‐Analysis

Immunity, Inflammation and Disease, Volume 14, Issue 9, September 2026.
ABSTRACT Objectives Respiratory syncytial virus (RSV) is a major cause of infant morbidity and mortality worldwide. Recent preventive strategies include maternal vaccination and monoclonal antibodies. However, maternal RSV vaccination has raised safety concerns due to possible associations with preterm birth.
Niko Leskinen, Marjut Haapanen, Ilari Kuitunen   +2 more
wiley   +1 more source

Impact du nirsevimab sur les infections pédiatriques au VRS en Belgique en 2024-2025 : une analyse des données de surveillance sentinelle de routine de Sciensano

Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source

Estimating the National Disease Burden and Economic Burden of Respiratory Syncytial Virus (RSV) in Thailand

Influenza and Other Respiratory Viruses, Volume 20, Issue 9, September 2026.
ABSTRACT Background Respiratory syncytial virus (RSV), a single‐stranded negative‐sense RNA virus, causes respiratory tract infections in children and adults, leading to hospitalization and mortality. However, the national disease burden and economic impact of RSV in Thailand remain undetermined.
Kansak Boonpattharatthiti, Chonnamet Techasaensiri, Wanatpreeya Phongsamart, Pilailuk Akkapaiboon Okada, Chanthawat Patikorn, Prabda Praphasiri, Teerapon Dhippayom, Nathorn Chaiyakunapruk   +7 more
wiley   +1 more source